Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.

Some cases of chronic myelogenous leukemia are resistant to tyrosine kinase inhibitors (TKIs) independently of mutation in BCR-ABL, but the detailed mechanism underlying this resistance has not yet been elucidated. In this study, we generated a TKI-resistant CML cell line, K562R, that lacks a mutation in BCR-ABL. Interleukin-1β (IL-1β) was more highly expressed in K562R than in the parental cell line K562S, and higher levels of IL-1β contributed to the imatinib resistance of K562R. In addition, IL-1β secreted from K562R cells affected stromal cell production of CXCL11, which in turn promoted migration of K562R cells into the stroma. Thus, elevated IL-1β production from TKI-resistant K562R cells may contribute to TKI resistance by increasing cell viability and promoting cell migration.

Lee CR ，Kang JA ，Kim HE ，Choi Y ，Yang T ，Park SG ... -  《-》

Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.

Hekmatshoar Y ，Ozkan T ，Altinok Gunes B ，Bozkurt S ，Karadag A ，Karabay AZ ，Sunguroglu A ... -  《-》

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.

Bandyopadhyay S ，Li J ，Traer E ，Tyner JW ，Zhou A ，Oh ST ，Cheng JX ... -  《-》

A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.

Chen CW ，Lee YL ，Liou JP ，Liu YH ，Liu CW ，Chen TY ，Huang HM ... -  《-》

Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.

Ozkan T ，Hekmatshoar Y ，Pamuk H ，Ozcan M ，Yaman G ，Yagiz GC ，Akdemir C ，Sunguroglu A ... -  《-》